Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

786 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PERK/eIF2α signaling protects therapy resistant hypoxic cells through induction of glutathione synthesis and protection against ROS.
Rouschop KM, Dubois LJ, Keulers TG, van den Beucken T, Lambin P, Bussink J, van der Kogel AJ, Koritzinsky M, Wouters BG. Rouschop KM, et al. Among authors: lambin p. Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):4622-7. doi: 10.1073/pnas.1210633110. Epub 2013 Mar 7. Proc Natl Acad Sci U S A. 2013. PMID: 23471998 Free PMC article.
Hypoxia as a target for combined modality treatments.
Wouters BG, Weppler SA, Koritzinsky M, Landuyt W, Nuyts S, Theys J, Chiu RK, Lambin P. Wouters BG, et al. Among authors: lambin p. Eur J Cancer. 2002 Jan;38(2):240-57. doi: 10.1016/s0959-8049(01)00361-6. Eur J Cancer. 2002. PMID: 11803141 Review.
Tumor-specific gene delivery using genetically engineered bacteria.
Theys J, Barbé S, Landuyt W, Nuyts S, Van Mellaert L, Wouters B, Anné J, Lambin P. Theys J, et al. Among authors: lambin p. Curr Gene Ther. 2003 Jun;3(3):207-21. doi: 10.2174/1566523034578357. Curr Gene Ther. 2003. PMID: 12762480 Review.
Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer.
De Ruysscher D, Pijls-Johannesma M, Bentzen SM, Minken A, Wanders R, Lutgens L, Hochstenbag M, Boersma L, Wouters B, Lammering G, Vansteenkiste J, Lambin P. De Ruysscher D, et al. Among authors: lambin p. J Clin Oncol. 2006 Mar 1;24(7):1057-63. doi: 10.1200/JCO.2005.02.9793. J Clin Oncol. 2006. PMID: 16505424
786 results